264

IMSUT Hospital

Department of Diagnostic Pathology
病理診断科

Department of Pathology
病理部

Associate Professor
Yasunori Ota, M.D., Ph.D.
Project Assistant Professor Tamami Denda, Ph.D.

准教授
特任助教

博士（医学）
博士（保健学）大傳田田泰珠徳美

Our mission
1. W
 e provide an accurate and high-quality pathological diagnosis to the patient inthis research hospital, The Institute of Medical Science, The University Of Tokyo.
2. Make diagnosis by morphological approach using microscope to the laboratory
materials.
Overview
We study about the hematological malignancy and transplantation pathology. Weemphasize many clinical cases and write case reports about human diseases.
We also perform pathological and cytological diagnosis of many specimens
submitted by various departments.

1. HHV8 negative effusion-based lymphoma has
been adopted for the new WHO classification.
Effusion-based lymphoma is found in pleura or
ascites and usually lack of evidence for nodular lesion. Conventional findings about EBL are bad clinical course and many patients are infected by HIV.
However, some of Japanese patients were not infected HIV and good clinical course. We reported somecase reports about EBL in Japan and are going to promote multi-institutional joint research in Japan. We
therefore conducted a retrospective study of 95 patients with EBL, regardless of HHV8 status, in Japan.
Of 69 patients with EBL tested for HHV8, a total of 64
were negative. The median age of patients with primary HHV8-negative EBL at diagnosis was 77 years(range, 57-98 years); all 58 tested patients were negative for HIV. Primary HHV8-negative EBL was mostcommonly diagnosed in pleural effusion (77%). Expression of at least 1 pan B-cell antigen (CD19, CD20,or CD79a) was observed in all cases. According to theHans algorithm, 30 of the 38 evaluated patients had
nongerminal center B-cell (non-GCB) tumors. Epstein-Barr virus–encoded small RNA was positive in
6 of 45 patients. In 56 of 64 HHV8-negative patients,systemic therapy was initiated within 3 months afterdiagnosis. Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like regimens with or without rituximab (n=48) were themost common primary treatments. The overall response and complete response rates were 95% and73%, respectively. Three patients did not progress
without systemic treatment for a median of 24 months.
With a median 25-month follow-up, the 2-year overall
survival and progression-free survival rates were
84.7% and 73.8%. Sixteen patients died; 12 were lym-

265
phoma-related deaths. Thus, most EBL cases in Japan
are HHV8-negative and affect elderly patients. The
non-GCB subtype is predominant. Overall, primary
HHV8-negative EBL exhibits a favorable prognosis
after anthracycline-based chemotherapy.
This disease concept has been adopted for the new
WHO classification of hematolymphoid tumor.
2.  Medical Activities
We have performed microscopic diagnosis ofmany pathological and cytological samples. We also
provided immunohistochemical analysis and in situ
hybridization in order to improve the diagnostic accuracy and decide the treatment.
Pathological diagnosis
n = 1540

BiopsySurgical resection
Bone marrow aspiration
Intraoperative diagnosis
Consultation
Other
Cytological diagnosis
Autopsyn = 959
n = 294n = 176n = 22n = 78n = 11n = 445
n=33.  Pathology Core Laboratory IIPathology Core Laboratory II handles a large
number of specimens, including mouse, cultured cells
and human tissue samples collected at the IMSUT
hospital. We have performed preparation of pathological specimen and pathological analysis (n = 71).

Publications
1.		Emi Sugimoto, Jingmei Li, Yasutaka Hayashi, Kohei Iida, Shuhei Asada, Tsuyoshi Fukushima, MoeTamura, Shiori Shikata, Wenyu Zhang, Keita
Yamamoto, Kimihito Cojin Kawabata, Tatsuya Kawase, Takeshi Saito, Taku Yoshida, SatoshiYamazaki, Yuta Kaito, Yoichi Imai, Tamami Denda, Yasunori Ota, Tomofusa Fukuyama, YosukeTanaka, Yutaka Enomoto, Toshio Kitamura, Susumu Goyama. Hyperactive Natural Killer cells inRag2 knockout mice inhibit the development ofacute myeloid leukemia. Commun Biol. 2023 Dec
21;6(1):1294. doi: 10.1038/s42003-023-05606-3.(2023)
2.		Miyazaki H, Hoshi N, Ishida T, Nishioka C, Ouchi
S, Shirasaka D, Yoshie T, Munetomo Y, Sakamoto
Y, Osuga T, Matsui S, Hyodo T, Denda T, Watanabe
D, Ooi M, Kodama Y. Association of CD4-positive
cell infiltration with response to vedolizumab inpatients with ulcerative colitis. Sci Rep. 2023 Nov
20;13(1):20262. doi: 10.1038/s41598-023-47618-3.
(2023)
3.		Sayaka Nagao, Yu Takahashi, Tamami Denda,
Yukihisa Tanaka, Yuko Miura, Hiroya Mizutani,
Daisuke Ohki, Yoshiki Sakaguchi, Seiichi Yakabi,
Yosuke Tsuji, Keiko Niimi, Naomi Kakushima,
Nobutake Yamamichi, Yasunori Ota, KazuhikoKoike, Mitsuhiro Fujishiro. Reduced DEFA5 Expression and STAT3 Activation Underlie the Submucosal Invasion of Early Gastric Cancers. Digestion. 2023 Aug 18;1-14. doi: 10.1159/000531790.
Online ahead of print.(2023)
4.		Keisuke Baba, Yasuo Matsubara, Yoshihiro Hirata,
Yasunori Ota, Satoshi Takahashi, Narikazu Boku.

Case report: Irinotecan-induced interstitial lungdisease in an advanced colorectal cancer patient
resurfacing decades after allogeneic bone marrowtransplantation for aplastic anemia; a case reportand narrative review of literature. Front Oncol.
2023; 13: 1215789.Published online 2023 Jun 16.
doi: 10.3389/fonc.2023.1215789. (2023)
5.		Aki Sato, Masayuki Kobayashi, Nozomi Yusa,
Miho Ogawa, Eigo Shimizu, Toyotaka Kawamata,Kazuaki Yokoyama, Yasunori Ota, Tatsuo Ichinohe, Hitoshi Ohno, Yasuo Mori, Emiko Sakaida,Tadakazu Kondo, Seiya Imoto, Yasuhito Nannya,
Kinuko Mitani, Arinobu Tojo. Clinical and prognostic features of Langerhans cell histiocytosis inadults. Cancer Sci. 2023 Jun 26. doi: 10.1111/cas.
15879. Online ahead of print.(2023)
6.		Hans Jiro Becker, Reiko Ishida, Adam C Wilkinson, Takaharu Kimura, Michelle Sue Jann Lee, Cevayir Coban, Yasunori Ota, Yosuke Tanaka, MeikeRoskamp, Tsubasa Sano, Arinobu Tojo, David GKent, Satoshi Yamazaki. Controlling genetic heterogeneity in gene-edited hematopoietic stem cellsby single-cell expansion. Cell Stem Cell. 2023 Jul
6;30(7):987-1000.e8. doi: 10.1016/j.stem.2023.06.002.
Epub 2023 Jun 28. (2023)
7.		Koichi Yabunaka, Haruka Oshima, Yasunori Ota,
Masayo Matsuzaki. Ultrasonographic Evaluationof Intravenous Lobular Capillary Hemangioma inthe Cephalic Vein. J Med Ultrasound. 2023 Jan-Mar;
31(1): 66–68. Published online 2022 May 27. doi:
10.4103/jmu.jmu_210_21 (2023)